中国神经再生研究(英文版) ›› 2022, Vol. 17 ›› Issue (12): 2771-2777.doi: 10.4103/1673-5374.339490

• 原著:脑损伤修复保护与再生 • 上一篇    下一篇

白细胞介素17A缺陷可减轻糖尿病脑病的神经炎症和认知功能障碍

  

  • 出版日期:2022-12-15 发布日期:2022-05-05
  • 基金资助:
    江苏省自然科学基金项目(BK20180948);南通应用研究计划项目(MS12019011);南通大学科技计划项目(TDYXY2019007)

Interleukin 17A deficiency alleviates neuroinflammation and cognitive impairment in an experimental model of diabetic encephalopathy

Xiao-Xia Fang, Fen-Fen Xu, Zhan Liu, Bei-Bei Cao, Yi-Hua Qiu*, Yu-Ping Peng*   

  1. Department of Physiology, School of Medicine, and Co-innovation Center of Neuroregeneration, Nantong University, Nantong, Jiangsu Province, China
  • Online:2022-12-15 Published:2022-05-05
  • Contact: Yi-Hua Qiu, PhD, yh_qiu@yeah.net; Yu-Ping Peng, PhD, yp_peng@yeah.net.
  • Supported by:
    This work was supported by the Natural Science Foundation of Jiangsu Province of China, No. BK20180948 (to ZL), Nantong Applied Research Program of China, No. MS12019011 (to XXF), and Science and Technology Project of Nantong University of China, No. TDYXY2019007 (to XXF). 

摘要:

既往研究显示,白细胞介素17是糖尿病及其并发症的关键促炎因子,但其在糖尿病脑病中的作用尚未完全阐明。实验通过白细胞介素17A敲除小鼠与转基因糖尿病模型Ins2Akita (Akita)杂交获得了白细胞介素17A敲除的糖尿病脑病小鼠模型。通过与野生型小鼠进行比较发现,糖尿病脑病小鼠血清、脑脊液和海马中白细胞介素17A水平增加,且认知能力下降,海马神经元丢失增加,小胶质细胞激活,同时血清和海马中炎症因子表达增加,而白细胞介素17A缺陷可减轻糖尿病脑病小鼠上述表现。提示白细胞介素17A参与糖尿病脑病病理过程,且白细胞介素17A缺陷可减轻糖尿病脑病的神经炎症和认知障碍。

https://orcid.org/0000-0001-5018-9575 (Yi-Hua Qiu)

关键词: 白细胞介素17A, 糖尿病脑病, Akita小鼠, 认知障碍, 小胶质细胞, 神经元, 神经炎症, 海马, 细胞凋亡, 靶向治疗

Abstract: Interleukin 17A (IL-17A) was previously shown to be a key pro-inflammatory factor in diabetes mellitus and associated complications. However, the role of IL-17A in diabetic encephalopathy remains poorly understood. In this study, we established a mouse model of diabetic encephalopathy that was deficient in IL-17A by crossing Il17a–/– mice with spontaneously diabetic Ins2Akita (Akita) mice. Blood glucose levels and body weights were monitored from 2–32 weeks of age. When mice were 32 weeks of age, behavioral tests were performed, including a novel object recognition test for assessing short-term memory and learning and a Morris water maze test for evaluating hippocampus-dependent spatial learning and memory. IL-17A levels in the serum, cerebrospinal fluid, and hippocampus were detected with enzyme-linked immunosorbent assays and real-time quantitative polymerase chain reaction. Moreover, proteins related to cognitive dysfunction (amyloid precursor protein, β-amyloid cleavage enzyme 1, p-tau, and tau), apoptosis (caspase-3 and -9), inflammation (inducible nitric oxide synthase and cyclooxygenase 2), and occludin were detected by western blot assays. Pro-inflammatory cytokines including tumor necrosis factor-α, interleukin-1β, and interferon-γ in serum and hippocampal tissues were measured by enzyme-linked immunosorbent assays. Microglial activation and hippocampal neuronal apoptosis were detected by immunofluorescent staining. Compared with that in wild-type mice, mice with diabetic encephalopathy had higher IL-17A levels in the serum, cerebrospinal fluid, and hippocampus; downregulation of occludin expression; lower cognitive ability; greater loss of hippocampal neurons; increased microglial activation; and higher expression of inflammatory factors in the serum and hippocampus. IL-17A knockout attenuated the abovementioned changes in mice with diabetic encephalopathy. These findings suggest that IL-17A participates in the pathological process of diabetic encephalopathy. Furthermore, IL-17A deficiency reduces diabetic encephalopathy-mediated neuroinflammation and cognitive defects. These results highlight a role for IL-17A as a mediator of diabetic encephalopathy and potential target for the treatment of cognitive impairment induced by diabetic encephalopathy.

Key words: Akita mice, apoptosis, cognitive impairment, diabetic encephalopathy, hippocampus, interleukin 17A, mice, microglia, neuroinflammation, neuron, targeted treatment